埃索美拉唑联合莫沙必利对反流性食管炎患者血清PG、GAS及炎性因子的影响

Effects of esomeprazole combined with mosapride on serum PG,GAS and inflammatory factors in patients with reflux esophagitis

目的 探讨对反流性食管炎患者采用埃索美拉唑联合莫沙必利治疗的临床疗效及对胃泌素(GAS)、胃蛋白酶原(PG)以及炎性因子水平的影响。方法 120例反流性食管炎患者,按照随机数字表法分为对照组和实验组,每组60例。对照组患者采用埃索美拉唑治疗,实验组患者采用埃索美拉唑联合莫沙必利治疗。比较两组患者临床疗效及治疗前后患者血清GAS、PG以及炎性因子[白细胞介素-2(IL-2)、白细胞介素-6(IL-6)]水平。结果 实验组患者治疗总有效率为96.67%(58/60),高于对照组的83.33%(50/60),差异具有统计学意义(P<0.05)。治疗后,两组患者PGⅠ水平高于本组治疗前,GAS17、PGⅡ水平低于本组治疗前,且实验组患者PGⅠ(125.62±12.70)μg/L高于对照组的(103.59±13.12)μg/L,GAS17(15.61±2.80)pmol/L、PGⅡ(15.92±3.45)μg/L低于对照组的(18.59±3.12)pmol/L、(19.74±3.31)μg/L,差异具有统计学意义(P<0.05)。治疗后,两组患者IL-2、IL-6水平均低于本组治疗前,且实验组患者IL-2(32.46±5.28)ng/L、IL-6(30.41±5.30)ng/L低于对照组的(43.17±7.20)、(40.56±5.18)ng/L,差异具有统计学意义(P<0.05)。结论 对反流性食管炎患者采用埃索美拉唑联合莫沙必利治疗疗效理想,有利于改善消化系统功能,减轻机体炎症反应,值得推广。

Objective To discuss the effects of esomeprazole combined with mosapride on serum gastrin(GAS),pepsinogen(PG)and inflammatory factors in patients with reflux esophagitis.Methods A total of 120 patients with reflux esophagitis were divided into control group and experimental group according to the random numerical table,with 60 cases in each group.Patients in the control group were treated with esomeprazole,and patients in the experimental group were treated with esomeprazole combined with mosapride.The clinical efficacy and the levels of serum GAS,PG and inflammatory factors[interleukin-2(IL-2)and interleukin-6(IL-6)]before and after treatment were compared between the two groups.Results The total effective rate in the experimental group was 96.67%(58/60),which was higher than 83.33%(50/60)in the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of PGⅠin the two groups were higher than those before treatment in this group,the levels of GAS17 and PGⅡwere lower than those before treatment in this group;the PGⅠ(125.62±12.70)μg/L in the experimental group was higher than(103.59±13.12)μg/L in the control group,and the GAS17(15.61±2.80)pmol/L,PGⅡ(15.92±3.45)μg/L were lower than(18.59±3.12)pmol/L,(19.74±3.31)μg/L in the control group;all the differences were statistically significant(P<0.05).After treatment,the levels of IL-2 and IL-6 in the two groups were lower than those before treatment in this group,and the IL-2(32.46±5.28)ng/L and IL-6(30.41±5.30)ng/L in the experimental group were lower than(43.17±7.20)and(40.56±5.18)ng/L in the control group.All the differences were statistically significant(P<0.05).Conclusion Esomeprazole combined with mosapride is effective in the treatment of patients with reflux esophagitis.It is beneficial to improve the function of the digestive system and reduce the body's inflammation.It is worthy of promotion.